Delcath Systems Stock News

Northern Trust Corp purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 12,743 shares of the companys stock, valued at approximately $161,000. Other large investors also recently added to or reduced their stakes [] The post Northern Trust Corp Purchases New Shares in Delcath Systems, Inc. (NASDAQ:DCTH) appeared first on ETF Daily News .

Agenus Inc. (AGEN) with the stream of -3.31% also noticed, India Delcath Systems, Inc. (DCTH) encountered a rapid change of -13.36% in the last hour of Fridays trading session. Agenus The post Miraculous Stock: Agenus Inc. (NASDAQ:AGEN), Delcath Systems, Inc. (NASDAQ:DCTH) appeared first on Stocks Equity .

Delcath Systems Inc (NASDAQ: DCTH ) has announced results from the Phase 3 FOCUS study of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma. The FOCUS study''s intent-to-treat (ITT) population included 102 subjects. Of the ITT group, 91 evaluable patients were administered at least one study treatment. The ITT analysis resulted in an objective response rate (ORR) of 31.4%, including 6.9% of patients with a complete response (CR) for Hepzato treatment. The median duration of Full story available on Benzinga.com

Delcath Systems Inc (NASDAQ: DCTH) has announced results from the Phase 3 FOCUS study of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant

On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall survival data continues to mature, a Hazard Ratio (HR) analysis of survival at 12-months yielded a statistically significant advantage for HEPZATO over a Best Alternative Care (BAC) arm [HR=0.37, p=0.01] in patients who received one or more treatments HEPZATO had statistically significant improvements over BAC in predefined exploratory analyses on ORR, DCR and PFS NDA resubmission for HEPZATO expected by mid-2022 NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive results from the phase 3 FOCUS study. The FOCUS study''s intent-to-treat (ITT) population was comprised of a total of 102 subjects, across various lines of therapy. Of the ITT group, 91 evaluable patients were administered at least one study treatment.

Focus Trial Data and Future Development Plans to be Discussed by Management and KOLs Focus Trial Data and Future Development Plans to be Discussed by Management and KOLs

Delcath Systems (DCTH) CEO, Gerard Mitchell on Q3 2021 Results - Earnings Call Transcript

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -3.30% and -9.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the sto

Delcath Systems (NASDAQ:DCTH) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Delcath Systems, Inc. (DCTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, anno

NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announce

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2021 Results - Earnings Call Transcript

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 2.04% and 34.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, toda